4:23 PM ET
8-K
Business Update
Biomarin Pharmaceutical Business Update
BioMarin disclosed the estimated financial impact of its August 31, 2026, acquisition of Alesta Therapeutics, including a $283 million pre-tax charge for acquired in-process research and development (IPR&D). The acquisition is expected to have a $1.50 unfavorable impact on Q3 2026 EPS and a $1.55 impact on full-year 2026 EPS, with updated full-year guidance to be provided during the Q3 earnings call.
- Counterparty
- Alesta Therapeutics B.V.